Citigroup Inc Tango Therapeutics, Inc. Transaction History

Citigroup Inc

$153 Billion
Q2 2024

A detailed history of Citigroup Inc transactions in Tango Therapeutics, Inc. stock. As of the latest transaction made, Citigroup Inc holds 22,065 shares of TNGX stock, worth $130,624. This represents 0.0% of its overall portfolio holdings.

Number of Shares

22,065

Previous 191,433 88.47%

Holding current value

$130,624

Previous $1.52 Million 87.56%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 12, 2024	SELL	$6.66 - $10.15 $1.13 Million - $1.72 Million	-169,368 Reduced 88.47%	22,065 $189,000
Q1 2024 May 10, 2024	BUY	$7.51 - $12.88 $1.38 Million - $2.36 Million	183,270 Added 2245.13%	191,433 $1.52 Million
Q4 2023 Feb 09, 2024	BUY	$6.52 - $12.01 $45,281 - $83,409	6,945 Added 570.2%	8,163 $80,000
Q3 2023 Nov 09, 2023	SELL	$2.93 - $11.26 $43,686 - $167,886	-14,910 Reduced 92.45%	1,218 $13,000
Q2 2023 Aug 10, 2023	BUY	$2.67 - $4.7 $21,191 - $37,303	7,937 Added 96.9%	16,128 $53,000
Q1 2023 May 11, 2023	SELL	$3.76 - $8.06 $8,091 - $17,345	-2,152 Reduced 20.81%	8,191 $32,000
Q4 2022 Feb 09, 2023	SELL	$3.41 - $8.29 $4,941 - $12,012	-1,449 Reduced 12.29%	10,343 $74,000
Q3 2022 Nov 10, 2022	SELL	$3.25 - $5.46 $5,694 - $9,565	-1,752 Reduced 12.94%	11,792 $43,000
Q2 2022 Aug 10, 2022	SELL	$3.86 - $8.01 $89,416 - $185,551	-23,165 Reduced 63.1%	13,544 $61,000
Q1 2022 May 12, 2022	BUY	$7.01 - $10.94 $29,911 - $46,680	4,267 Added 13.15%	36,709 $278,000
Q4 2021 Feb 10, 2022	BUY	$9.55 - $14.29 $279,557 - $418,311	29,273 Added 923.73%	32,442 $355,000
Q3 2021 Nov 10, 2021	BUY	$9.56 - $17.3 $30,295 - $54,823	3,169 New	3,169 $41,000

Others Institutions Holding TNGX

# of Institutions

121

Shares Held

89.1M

Call Options Held

2.6K

Put Options Held

View Full List

About Tango Therapeutics, Inc.

Ticker TNGX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 88,067,296
Market Cap $521M
Description
Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company also develops...

More about TNGX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

News

Stay updated on Citigroup Inc with notifications on news.

Account